Contents
Contents
Medical device sales incentives influence hospital purchasing through the people who choose, supply and use the product. A surgeon may choose the implant, a hospital buys it, and a manufacturer or distributor earns the sale. Medicare usually pays the institution for the procedure or stay, with the implant included. If you work in medical device sales, the operating room or hospital purchasing, you may see the same operation as a commission, an inventory movement or an acquisition cost. Those records meet at the patient’s procedure.
Implant selection gives the physician influence over money the hospital spends. The HHS Office of Inspector General calls implantable medical devices physician preference items because the physician may strongly influence both the brand and the type. Its alert on physician-owned entities identifies the commercial opening: the person choosing the product can also have a financial interest in selling it.
The hospital or surgery center approves products and buys them. Group purchasing organizations negotiate supplier contracts for participating hospitals and other health care facilities. A health system’s purchasing agreement can therefore sit between a surgeon’s preference and the price the hospital pays. Medtronic’s fiscal 2026 filing describes negotiating with both group purchasing organizations and integrated delivery networks that contract for their member facilities.
Hospital value analysis has to connect that clinical choice with the institution’s purchasing terms. The perioperative nursing association’s position on industry representatives identifies a specific concern: representatives influencing product selection and bringing products into a facility that do not comply with its existing contracts. The product the surgeon wants and the product covered by the purchasing agreement can be different.
We connect what was requested and used with the agreement under which the hospital bought it. The customer’s report of product use supplies the event that can trigger the manufacturer’s sale.
Medical device distribution includes direct sales employees, independent agents and businesses that buy and resell products. The word distributor can conceal an important difference in their jobs. A Senate Finance Committee staff report describes independent sales agencies that the industry calls distributors even when the medical device goes directly from the manufacturer to the hospital.
The committee’s 2011 account of the implant supply chain includes ordering, delivery, stocking, restocking, instrumentation and assistance to surgeons in the operating room. The representative can be responsible for getting the product and equipment to the case as well as winning the business.
Zimmer Biomet’s fiscal 2025 filing distinguishes direct hospital and surgery-center accounts from stocking distributors and healthcare dealers. Orthofix describes regional and territory managers overseeing independent distributors and sales agents. For someone inside that channel, the useful questions are who holds the inventory, who invoices the hospital and who receives compensation when the medical device is used.
The product mix changes what that channel has to supply. Medline’s filing describes surgical and procedural kits, gloves and other consumable supplies. Orthofix describes implant sets that travel with the instruments needed for surgery. A hospital receives both kinds of goods, but an implant set also has to offer the sizes the physician may need during the operation. The product, the accompanying equipment and the representative’s work belong together when we examine what the hospital bought.
The nursing association also gives the representative’s presence a place in the medical record. Its position calls for credentialing and identification and for recording the representative’s name, company and time in the room. It restricts direct patient care and sterile-field activity. That entry can connect a particular representative with a particular operation.
A group purchasing organization can earn a supplier-paid fee on member purchases while the hospital receives its own negotiated price and revenue share. The fee, the distributor’s markup and the hospital’s acquisition cost belong to different participants.
The HealthTrust agreement with Cardiovascular Systems, effective August 2014, makes the arrangement unusually concrete. It covered an orbital atherectomy system. Its fee clause required the vendor to pay HealthTrust on covered purchases even when a member paid a different price or purchased under a separate agreement. The clause also covered purchases through a distributor.
The agreement required purchaser-level reporting even when the vendor used its own customer identification numbers. The facility’s ship-to address and purchasing identifier had to travel with the purchase information. Those details let the report connect a system’s purchasing relationship with the particular facility buying the product.
The calculation excluded distributor markup and specified other exclusions, including freight, taxes and rebates. Rebates, when specified, went through HealthTrust for payment to purchasers.
Premier Inc.’s filing for the fiscal year ended June 2025 describes supplier administrative fees generally representing 1% to 3% of the purchase price under its contracts. Premier shared part of its gross fees with members and recorded that share as a reduction in revenue. It also stated that it did not take title to the underlying products.
These arrangements create records beyond the hospital’s invoice: supplier purchase reports, fee calculations and member revenue shares. We examine them together when the question is who benefited from a purchasing decision. A single invoice can show the hospital’s price while leaving those other payments elsewhere in the accounts.
Consigned implants can sit in a hospital while the manufacturer still owns them. Use or implantation can trigger the sale. Delivery to a shelf and sale to the hospital are different events.
Zimmer Biomet reported that consignment sales represented approximately 85 percent of its net sales in 2025. Its filing said it retained title to consigned inventory and placed inventory with sales agents or customers.
Medtronic’s filing distinguishes products whose control transfers at shipment or delivery, certain capital equipment whose control transfers at installation, and consigned products whose control transfers when used or implanted. An installed equipment system and an implant taken from a consignment tray reach the sale at different points.
Edwards Lifesciences likewise described recognizing consignment revenue when the customer implanted or used the product. It said it periodically reviewed consignment inventory to confirm the accuracy of customer reporting. The manufacturer’s revenue record depended on information coming back from the customer.
The tray itself explains why inventory can remain after a completed operation. Orthofix described sets containing instruments and implants in several sizes so the physician could select the appropriate implant. Its filing said a typical surgery used only some of the implants in the set. It also described leaving sets at hospitals with high procedure volumes and sending other sets through independent agents for individual procedures.
For an insider, the relevant sequence is the stock delivered, the product used, the use reported and the sale recorded. We connect those events to the patient procedure and the institutional bill. The consignment arrangement supplies both an inventory trail and a reason the sales team cares about what happens in the room.
Zimmer Biomet’s fiscal 2025 filing said its U.S. sales force received commissions on product sales and was responsible for many operating decisions and costs.
The same filing described volume discounts used to promote unit growth. Under its group purchasing contracts, Zimmer generally became one of several preferred sources for specified products, while members remained free to buy elsewhere. Contract access and actual product use were separate commercial achievements.
That distinction matters when we examine a sales target. We want to understand whose purchases earned the payment, which products counted and what the representative did to increase use. A compensation statement answers who earned a commission. The purchasing and procedure records answer which sales produced it.
The operating responsibilities matter too. Stocking a hospital, supplying instrument sets and supporting a procedure all appear in the documented distribution model. To understand what a payment purchased, we put the compensation arrangement beside the work performed and the medical device sales attributed to it.
A medical device manufacturer pays for the equipment that supports a sale as well as the people who win it.
Boston Scientific’s fiscal 2025 segment disclosure reported selling, general and administrative expense equal to 31% of MedSurg segment net sales, compared with cost of sales at 28.10% of that same denominator. The combined commercial and administrative expense exceeded the reported cost of the goods.
There is real equipment inside that expense category. Stryker described including amortization of loaner instrumentation in selling, general and administrative expense, alongside marketing, administration and other overhead. Boston Scientific also placed ordinary legal costs in that combined line.
Distribution has its own economics. Cardinal Health’s Global Medical Products and Distribution segment reported $12.719 billion in revenue and $258 million in segment operating income for the fiscal year ended June 2026.
For the whistleblower inquiry, the public filing supplies scale. The particular commission, consulting payment, distributor return or rebate supplies the transaction we need to understand. We connect it to the purchasing decision and the patient care that followed.
Medicare usually includes an implanted medical device in payment for the hospital procedure or stay. The hospital separately records what it paid to acquire the medical device.
A medical device code or charge can still appear on a hospital claim when the medical device is included in the procedure payment. Someone tracing a sale therefore needs both the acquisition record and the institutional claim. Looking for a separately paid implant line can miss the payment associated with its use.
There are defined additional-payment routes. Qualifying inpatient technologies can receive a new technology add-on payment. Hospital outpatient medical devices in qualifying categories can receive temporary transitional pass-through payment.
The hospital has to provide the care covered by its procedure or stay payment, so the medical device’s acquisition cost comes out of that payment. When we examine medical device fraud, we follow the commercial incentive through product selection and use to the claim the institution submitted.
Medical device cases show payments tied to implant selection through consulting arrangements and physician-owned distribution.
Life Spine’s 2019 civil settlement included admissions about management reports comparing surgeon payments with use of its spinal products. One report calculated a return on investment by dividing the sales associated with each surgeon by the consulting fees and royalties paid to that surgeon. When use declined, senior sales managers contacted surgeons or their distributors to urge more use. Management measured the return on paying a surgeon by how much product that surgeon used.
The whistleblower’s complaint described what those agreements allegedly rewarded:
The consulting relationship is not based on providing any follow-up product review, feedback or evaluation, or other consulting work, but instead based on a tacit condition that the physician-consultants use Life Spine products.
The complaint also alleged monthly product-use quotas for physician-consultants and demands for surgical schedules and weekly updates until usage increased. That is a sales target applied to the doctor choosing the implant. Patients depend on that choice, and Medicare and Medicaid pay for the procedures the government alleged those payments influenced.
Physician-owned distributorships put that incentive inside an ownership arrangement. HHS-OIG describes entities earning revenue from medical devices their physician-owners order for procedures on their own patients. The physician can influence the purchase and share in the seller’s return.
The government brought the case against Reliance Medical Systems directly. In the settlement announced in 2022, the government alleged referral-based distributions through physician-owned implant distributors and removal of physicians who generated insufficient referrals. The ownership records, distribution payments and implant orders described different parts of the alleged arrangement. The return allegedly followed the business the physician brought in.
We work with you to connect the payment that drove medical device selection to the product used and the institutional claim. A sales representative may know the target and the payment. Hospital staff may know the medical device used, the purchase terms and the bill.
The 2020 Journal of Forensic and Investigative Accounting paper, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, centers its False Claims Act analysis on the request for government payment. For medical device sales, that focus takes the inquiry from the manufacturer’s commercial records to the hospital’s claim.
The most revealing comparisons here are specific: consulting payments beside surgeon use, a fee report beside the purchases it includes, or consignment usage beside the operation and invoice. Life Spine’s management reports made one of those comparisons inside the business itself. The evidence can explain both how money moved and what conduct the company wanted that money to produce.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
If you know which surgeon payments, sales targets or distributor returns drove medical device use at a hospital, speak with our whistleblower experts about that purchasing decision. We connect your commercial knowledge to the medical devices used and the claims paid, build your strongest medical device whistleblower case with you, and bring in medical device fraud whistleblower lawyers who understand the sales channel. We stay beside you from that first account through the case.